Boehringer Sex Pill Fails to Win U.S. Panel’s Backing
This article is for subscribers only.
Boehringer Ingelheim GmbH failed to win a U.S. panel’s backing for its sexual desire drug flibanserin, providing a setback for the first pill designed to boost women’s libidos.
The treatment doesn’t provide enough benefits to outweigh potential risks to women such as fainting, outside advisers to the Food and Drug Administration said in an 11-0 vote today in Gaithersburg, Maryland. While the FDA usually follows its advisory panels’ recommendations, it isn’t required to do so.